The “Scars of Life” project aimed to explore how the age of onset of AD affects the severity of its symptoms and their impact on daily and occupational life [1]. The study included data from 30,801 adults in 27 countries on 5 continents. A questionnaire was developed in collaboration with multiple patient associations and international AD experts. It not only included questions related to AD severity but also questions regarding stigmatisation in professional and personal life.
This global project grouped participants based on whether their AD began in childhood, before age 10, or adulthood. To address potential biases in baseline characteristics between groups, a 1:1 propensity score matching with replacement was performed. The results were presented by Prof. Jonathan Silverberg (The George Washington University School of Medicine, Washington DC, USA).
Among 10,258 individuals with current AD, those with onset during childhood reported significantly higher levels of social and emotional distress compared with those with adult-onset AD. Specifically, people suffering from AD since childhood had a systematically higher sense of stigmatisation, as measured by the Patient Unique Stigmatization Holistic tool in dermatology (PUSH-D) score (23.0±20.1 vs 18.1±17.6; P<0.0001).
This stigma influenced all major life areas: 37.3% of those who suffered AD since childhood declared that they had faced discrimination at work compared with 29.4% who only had AD in adulthood. This stigma also influenced personal relationships. “If we drill down in subdomains—those with both childhood and adult AD had significantly worse outcomes. They avoid photos and avoid people or reduce contact with other people,” Prof. Silverberg said.
Furthermore, individuals with early-onset AD were more likely to feel that their disease had hindered their professional careers, family planning, and overall self-confidence, indicating that early-onset AD imposes a long-lasting psychosocial burden.
The "Scars of Life" project underscores the necessity of addressing not only the physical but also the social and emotional aspects of AD, particularly for individuals affected from childhood. “Chronicity appears to contribute to the overall disease burden above and beyond disease severity,” Prof. Silverberg concluded. Thus, AD necessitates early introduction of adequate long-term management.
- Silverberg JI. Impact of atopic dermatitis in adults depends on its age of onset: Results of the “Scars of Life” project. D1T01.2, FEADV Congress 2024, 25–28 September, Amsterdam, the Netherlands.
Copyright ©2024 Medicom Medical Publishers
Medical writing support provided by Dr Susanne Kammerer
Posted on
Previous Article
« PsoBest registry: Biologics have become the first choice in moderate-to-severe psoriasis Next Article
Prurigo nodularis: long-term treatment reduces relapse events »
« PsoBest registry: Biologics have become the first choice in moderate-to-severe psoriasis Next Article
Prurigo nodularis: long-term treatment reduces relapse events »
Table of Contents: EADV 2024
Featured articles
Delgocitinib cream outperforms oral alitretinoin in chronic hand eczema
Targeting IL-17A offers a promising treatment perspective in hidradenitis suppurativa
Online First
Delgocitinib cream outperforms oral alitretinoin in chronic hand eczema
Second-generation selective PDE-4 inhibitor shows promise in AD
HS: Bimekizumab shows sustained 2-year efficacy
JAK1 inhibitor shows promising long-term efficacy in PN
Deuruxolitinib significantly improves hair satisfaction in alopecia areata
Familial hidradenitis suppurativa associated with higher risk for metabolic disease
Targeting IL-17A offers a promising treatment perspective in hidradenitis suppurativa
Imsidolimab potential future therapeutic avenue for generalised pustular psoriasis
Prurigo nodularis: long-term treatment reduces relapse events
Atopic dermatitis early in life imposes a lifelong psychosocial burden
PsoBest registry: Biologics have become the first choice in moderate-to-severe psoriasis
Topical pan-JAK inhibitor mitigates inflammatory biomarkers in frontal fibrosing alopecia
Atopic hand eczema: similar treatment success for dupilumab and topical delgocitinib
IL-13 inhibitor shows safety and efficacy in AD over 3 years
Semaglutide: also beneficial for patients with HS?
Advanced BCC: histological subtype and time to complete response may predict tumour recurrence
New targets identified for chronic wound healing
Related Articles
October 1, 2024
Prurigo nodularis: long-term treatment reduces relapse events
May 31, 2024
Digital dermatology in the Dutch treatment landscape
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com